MSN 611 : Clinical Pharm & Intervention for APRNs - NKU

Correct Answer:

B - Some can reduce ventricular hypertrophy.

Explanation of the Correct Answer:

Renin-angiotensin-aldosterone system (RAAS) inhibitors, including ACE inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists (such as eplerenone), have been shown to have beneficial effects beyond blood pressure control. One of the key benefits is their ability to reduce ventricular hypertrophy (enlargement of the heart muscle), which is often associated with heart failure and chronic hypertension. By blocking different components of the RAAS, these medications reduce the workload on the heart, promote better cardiac function, and can help prevent further cardiac remodeling, including ventricular hypertrophy.

Why the Other Options Are Incorrect:

A - They are mostly considered adjunctive therapy for hypertension:

This statement is partially correct but not the best choice. While RAAS inhibitors are important in the management of hypertension, especially in cases of resistant hypertension or those with comorbid conditions like heart failure or chronic kidney disease, they are often considered first-line therapy in many hypertension guidelines, not just adjunctive.

C - Eplerenone interrupts the generation of angiotensin II by inhibiting renin within the RAAS cascade:

This statement is incorrect. Eplerenone is an aldosterone antagonist, not a direct inhibitor of renin. It works by blocking the effects of aldosterone at the mineralocorticoid receptor, rather than inhibiting the RAAS cascade or preventing the generation of angiotensin II. Other drugs, such as ACE inhibitors or ARBs, block the production of angiotensin II.

D - Aliskiren may cause gynecomastia in patients:

This statement is incorrect. Aliskiren is a direct renin inhibitor, and although it blocks the renin-angiotensin-aldosterone system, it does not cause gynecomastia. Gynecomastia is a side effect more commonly associated with spironolactone, an aldosterone antagonist, not with aliskiren.

Correct Answer:

B - Increased dopamine

Explanation of the Correct Answer:

Modafinil is a wakefulness-promoting agent that is commonly used to treat conditions such as narcolepsy, obstructive sleep apnea, and shift work sleep disorder. The exact mechanism of action of modafinil is not fully understood, but it is believed to work primarily by increasing dopamine levels in the brain. Modafinil inhibits the dopamine reuptake transporter, which increases dopamine availability in the synaptic cleft, leading to increased dopamine signaling. This effect helps to promote wakefulness and reduce daytime fatigue in individuals with sleep disorders like obstructive sleep apnea.

Why the Other Options Are Incorrect:

A - Increased serotonin:

While serotonin plays a role in regulating mood, sleep, and wakefulness, modafinil's primary mechanism is related to dopamine rather than serotonin. Selective serotonin reuptake inhibitors (SSRIs) or other serotonergic medications would more directly affect serotonin levels, not modafinil.

C - Increased acetylcholine:

Acetylcholine is involved in the regulation of attention, learning, and memory, and while some stimulants may influence acetylcholine levels, modafinil's primary mechanism is through dopamine, not acetylcholine.

D - Increased norepinephrine:

Although modafinil has some effects on norepinephrine, its primary mechanism is related to dopamine. Norepinephrine is more prominently targeted by medications like SNRIs (serotonin-norepinephrine reuptake inhibitors) or other sympathomimetic drugs, not modafinil.

Correct Answer:

B - usually diagnosed based on physical assessment.

Explanation of the Correct Answer:

Varicosities are typically diagnosed through physical assessment. The diagnosis is primarily based on the appearance of the veins in the lower extremities, which are often visible as dilated, tortuous veins. A clinician can usually identify varicose veins during a routine physical examination by inspecting the legs for swollen veins and may also assess for signs of chronic venous insufficiency. In some cases, additional tests like Doppler ultrasound may be used to assess the blood flow and valve function within the veins, but the diagnosis is generally made clinically.

Why the Other Options Are Incorrect:

A - most likely due to congenital valve deformities:

While congenital valve deformities can lead to varicosities, they are not the most common cause. The majority of cases are due to acquired valve dysfunction and venous insufficiency over time, often associated with aging, prolonged standing, obesity, or pregnancy.

C - indicative of an underlying cardiovascular disease:

Varicosities are a vascular issue rather than a cardiovascular disease. While they may be associated with venous insufficiency or other vascular conditions, they are not typically a sign of cardiovascular disease (such as coronary artery disease or heart failure). This makes option C less accurate.

D - more symptomatic during ovulation:

Although hormonal fluctuations during ovulation may exacerbate symptoms of varicose veins, this is not a defining characteristic of varicosities. The primary issue is chronic venous insufficiency and venous hypertension, not necessarily the timing within the menstrual cycle.

Correct Answer:

C - Protozoa.

Explanation of the Correct Answer:

Malaria is caused by a protozoan parasite belonging to the genus Plasmodium. The species responsible for malaria in humans include Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, and Plasmodium malariae. These parasites are transmitted through the bite of an infected female Anopheles mosquito. The protozoan enters the bloodstream and infects liver cells, later affecting red blood cells, leading to the symptoms of malaria.

Why the Other Options Are Incorrect:

A - Bacteria:

Bacteria cause a variety of infections, such as tuberculosis and pneumonia, but not malaria. Malaria is caused by a protozoan, not a bacterium.

B - Virus:

Malaria is not caused by a virus. Although viruses like the Zika virus or HIV can cause serious diseases, malaria is specifically caused by a protozoan parasite, not a viral pathogen.

D - Mycobacterium:

Mycobacterium refers to a genus of bacteria, which includes species like Mycobacterium tuberculosis (the cause of tuberculosis). Mycobacterium does not cause malaria.

Correct Answer:

D - Decrease in systemic vascular resistance

Explanation of the Correct Answer:

In the first trimester of pregnancy, a woman's body undergoes major cardiovascular changes to accommodate the growing fetus. One of the earliest and most significant changes is a decrease in systemic vascular resistance (SVR). This occurs because progesterone causes smooth muscle relaxation, leading to vasodilation of the peripheral blood vessels. The decreased resistance helps maintain blood flow to the uterus and developing placenta. Despite the fall in SVR, blood pressure often remains relatively stable or even slightly lower due to the body's compensatory mechanisms.

Why the Other Options Are Incorrect:

A - Decrease in preload:

This is incorrect because preload (the amount of blood returning to the heart) actually increases during pregnancy due to an expanded blood volume. The increase in plasma volume begins early in the first trimester, leading to an elevated preload, not a decrease.

B - Decrease in stroke volume:

This is incorrect because stroke volume (the amount of blood ejected by the heart with each beat) increases during pregnancy. The heart compensates for the increased volume demands by pumping more blood per beat, not less.

C - Decrease in cardiac output:

This is incorrect because cardiac output increases significantly during pregnancy. Cardiac output rises by about 30-50%, mainly due to the increases in both stroke volume and heart rate. Decreased cardiac output would be harmful to both the mother and the fetus.

Correct Answer:

C - Isoproterenol

Explanation of the Correct Answer:

In this scenario, the patient is presenting with 2nd-degree Mobitz type II heart block, which is often associated with a significant slowing of the heart rate (bradycardia). Isoproterenol, a beta-adrenergic agonist, is frequently used in such situations for pharmacologic pacing to increase the heart rate by stimulating the beta-1 receptors in the heart. It is effective at increasing heart rate, especially when there is heart block that is causing a low heart rate (like in this case with the patient’s pulse of 42 bpm). Isoproterenol works by enhancing AV node conduction and ventricular response. One notable side effect of isoproterenol is the potential to increase blood glucose levels due to its beta-2 adrenergic stimulation, which leads to glycogenolysis and the release of glucose into the bloodstream, explaining the elevated blood glucose of 210 in the patient hours later.

Why the Other Options Are Incorrect:

A - Epinephrine:

While epinephrine is a potent adrenergic agonist used in emergencies like anaphylaxis or in cases of severe bradycardia, it is not typically used as a first-line agent for heart block unless more severe hemodynamic instability is present. Additionally, epinephrine tends to have more potent effects on blood pressure and systemic vascular resistance, whereas isoproterenol is more specific for increasing heart rate and improving AV node conduction.

B - Atropine:

Atropine is often used for the treatment of symptomatic bradycardia, particularly in cases of sinus bradycardia or AV nodal block. However, it is less effective for 2nd-degree Mobitz type II heart block and would not be expected to have as profound an effect on increasing the heart rate as isoproterenol. Atropine is also less likely to increase blood glucose levels significantly.

D - Dopamine:

Dopamine is used in cases of shock and severe hypotension rather than in the management of heart block. It works by stimulating dopaminergic receptors to improve blood flow to vital organs, and at higher doses, it can stimulate beta-1 adrenergic receptors to increase heart rate and contractility. However, isoproterenol is a more direct and effective treatment for improving heart rate and pacing in the context of heart block, and it is more likely to be used in this situation.

Correct Answer:

C. Sulfonylureas

Explanation of the Correct Answer:

Dipeptidyl peptidase-4 (DPP-4) inhibitors are oral medications used in the management of type 2 diabetes. They work by inhibiting the DPP-4 enzyme, which normally breaks down incretins (such as GLP-1), leading to increased levels of these hormones. These incretins help enhance insulin secretion in response to meals and reduce glucagon secretion, thereby lowering blood glucose.

When DPP-4 inhibitors are combined with sulfonylureas, there is an increased risk of hypoglycemia. This is because both drugs enhance insulin secretion through different mechanisms. Sulfonylureas directly stimulate the pancreas to release insulin, while DPP-4 inhibitors indirectly increase insulin secretion by prolonging the action of incretins. The combined effect can result in excessive insulin production, leading to an increased risk of hypoglycemia, particularly if the patient misses meals, has renal impairment, or experiences other changes in their usual routine.

Why the Other Options Are Incorrect:

A. Biguanides (e.g., metformin)

Biguanides work by reducing hepatic glucose production and improving insulin sensitivity. They do not directly stimulate insulin secretion, and they do not increase the risk of hypoglycemia when used alone or with DPP-4 inhibitors. They are considered weight-neutral and are typically a first-line treatment for type 2 diabetes.

B. Thiazolidinediones (e.g., pioglitazone)

Thiazolidinediones improve insulin sensitivity in the muscles and adipose tissue. They do not directly influence insulin secretion, and therefore, they are not associated with an increased risk of hypoglycemia when used with DPP-4 inhibitors. However, they can cause fluid retention and have other potential side effects such as weight gain and edema.

D. GLP-1 receptor agonists

GLP-1 receptor agonists, like liraglutide, semaglutide, and others, mimic the action of GLP-1 by stimulating insulin secretion in response to meals and inhibiting glucagon release. Although they can help reduce blood glucose levels, they do not increase the risk of hypoglycemia when used with DPP-4 inhibitors. In fact, GLP-1 agonists generally have a lower risk of hypoglycemia compared to sulfonylureas because they only stimulate insulin release in the presence of elevated blood glucose levels.

Correct Answer:

B - Switch to another class of antidepressant

Explanation of the Correct Answer:

In this patient with left-sided chest pain, doxepin, a tricyclic antidepressant (TCA), should be discontinued due to its cardiovascular side effects, particularly its potential to exacerbate arrhythmias and QT interval prolongation. TCAs are known to have anticholinergic effects and can lead to prolonged QRS complexes, arrhythmias, and worsening of heart conduction in patients with existing heart conditions, such as left bundle branch block (LBBB). This patient’s LBBB on EKG suggests an underlying conduction abnormality, which puts him at increased risk of cardiac arrhythmias when taking TCAs. The best next step would be to switch him to a safer antidepressant with fewer cardiovascular effects, such as a selective serotonin reuptake inhibitor (SSRI), which would avoid the risks associated with TCAs.

Why the Other Options Are Incorrect:

A - Continue doxepin and monitor for symptoms:

Continuing doxepin in the setting of left bundle branch block and chest pain could be dangerous because the cardiovascular side effects of TCAs (such as conduction disturbances and arrhythmias) could exacerbate the patient's existing conduction abnormality and lead to life-threatening arrhythmias. Monitoring the patient without changing medications would not address the cardiac risks associated with TCAs.

C - Start nitroglycerin to relieve chest pain:

While nitroglycerin can be helpful in relieving angina and chest pain related to myocardial ischemia, the patient's left bundle branch block and doxepin use pose a greater concern. Nitroglycerin is contraindicated in some cases of congestive heart failure (CHF), especially if the patient is already on medications that lower preload, and it may cause hypotension. The priority here is managing the cardiac risk associated with the antidepressant rather than focusing solely on the chest pain. Treating the underlying cause of cardiac conduction abnormalities (via switching the antidepressant) is a more immediate concern.

D - Perform a coronary angiogram immediately:

While this patient is presenting with chest pain, a coronary angiogram would be more appropriate if there were signs of acute coronary syndrome (ACS), such as ST elevation or if the patient’s risk factors pointed to a myocardial infarction. However, his EKG shows left bundle branch block, not ST-segment elevation, and no clear evidence of ACS. The next step should focus on managing the medication he is taking, as doxepin could be contributing to his current symptoms and increasing his cardiovascular risk.

Correct Answer:

D - Increases glucose-dependent insulin secretion

Explanation of the Correct Answer:

Metformin (Glucophage) is a biguanide that primarily works by decreasing hepatic (liver) glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity in peripheral tissues such as skeletal muscle. Importantly, metformin does not stimulate insulin secretion from the pancreas. Unlike drugs such as sulfonylureas or incretin-based therapies, metformin does not act by increasing glucose-dependent insulin secretion. This distinction helps explain why metformin has a low risk of causing hypoglycemia compared to medications that increase insulin release.

Why the Other Options Are Incorrect:

A - Decreases glucose production by the liver:

This is a primary mechanism of action of metformin. It inhibits gluconeogenesis in the liver, leading to decreased fasting blood glucose levels.

B - Decreases intestinal absorption of glucose:

Metformin also reduces glucose absorption in the gastrointestinal tract, contributing to lower postprandial blood glucose levels.

C - Improves insulin sensitivity:

Metformin increases insulin sensitivity in peripheral tissues, particularly muscle, allowing for better glucose uptake and utilization without increasing insulin levels.